{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T11:05:25Z","timestamp":1693825525770},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.2169\/internalmedicine.2174-18","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T17:38:21Z","timestamp":1548956301000},"page":"1587-1591","source":"Crossref","is-referenced-by-count":5,"title":["Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease"],"prefix":"10.2169","volume":"58","author":[{"given":"Izumi","family":"Nagayama","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Masuda","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohara","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Clinical Engineering, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akito","family":"Maeshima","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Akimoto","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Muto","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nagata","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Cleland JG, Coletta A, Witte K. Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med 119: S26-S36, 2006.","DOI":"10.1016\/j.amjmed.2006.09.014"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mori T, Ohsaki Y, Oba-Yabana I, Ito S. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure. Hepatol Res 47: 11-22, 2017.","DOI":"10.1111\/hepr.12700"},{"key":"3","unstructured":"3. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13: 599-608, 2007."},{"key":"4","unstructured":"4. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V (2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292: 288-294, 2000."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 61: 169-174, 2013.","DOI":"10.1016\/j.jjcc.2012.08.020"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 64: 1772-1779, 2003.","DOI":"10.1046\/j.1523-1755.2003.00273.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Soderberg M, Hahn RG, Cederholm T. Bioelectric impedance analysis of acute body water changes in congestive heart failure. Scand J Clin Lab Invest 61: 89-94, 2001.","DOI":"10.1080\/00365510151097520"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Masuda T, Murakami T, Igarashi Y, et al. Dual impact of tolvaptan on intracellular and extracellular water in chronic kidney disease patients with fluid retention. Intern Med 55: 2759-2764, 2016.","DOI":"10.2169\/internalmedicine.55.7133"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Masuda T, Akimoto T, Ando Y, et al. Changes in the urinary excretion of beta2-microglobulin (beta 2MG) and N-acetyl-beta-D-glucosaminidase (NAG) during treatment for lupus nephritis. Intern Med 47: 287-290, 2008.","DOI":"10.2169\/internalmedicine.47.0464"},{"key":"10","unstructured":"10. Masuda T, Ohara K, Murakami T, et al. Sodium-glucose cotransporter 2 inhibition with dapagliflozin ameliorates extracellular volume expansion in diabetic kidney disease patients. POJ Diabetes Obes 1: 1-8, 2017."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nitta S, Ohnuki T, Ohkuda K, Nakada T, Staub NC. The corrected protein equation to estimate plasma colloid osmotic pressure and its development on a nomogram. Tohoku J Exp Med 135: 43-49, 1981.","DOI":"10.1620\/tjem.135.43"},{"key":"12","unstructured":"12. Ng Kam Chuen MJ, Lip GY, Macfadyen RJ. Performing repeated noninvasive bedside measures of volume response to intravenous furosemide in acute pulmonary edema: a feasibility assessment. Cardiovasc Ther 27: 89-95, 2009."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: time for a new approach? Circ Heart Fail 7: 531-535, 2014.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000828"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Stookey JD, Purser JL, Pieper CF, Cohen HJ. Plasma hypertonicity: another marker of frailty? J Am Geriatr Soc 52: 1313-1320, 2004.","DOI":"10.1111\/j.1532-5415.2004.52361.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Okada H, Takemura G, Suzuki K, et al. Three-dimensional ultrastructure of capillary endothelial glycocalyx under normal and experimental endotoxemic conditions. Crit Care 21: 261, 2017.","DOI":"10.1186\/s13054-017-1841-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol 53: 258-268, 2018.","DOI":"10.1007\/s00535-017-1366-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kogiso T, Kobayashi M, Yamamoto K, et al. The outcome of cirrhotic patients with ascites is improved by the normalization of the serum sodium level by tolvaptan. Intern Med 56: 2993-3001, 2017.","DOI":"10.2169\/internalmedicine.9033-17"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Association between the serum sodium levels and the response to tolvaptan in liver cirrhosis patients with ascites and hyponatremia. Intern Med 57: 2451-2458, 2018.","DOI":"10.2169\/internalmedicine.0629-17"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Katsumata M, Hirawa N, Sumida K, et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clin Exp Nephrol 21: 858-865, 2017.","DOI":"10.1007\/s10157-016-1379-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tominaga N, Kida K, Inomata T, et al. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study. Clin Exp Nephrol 2018 (Epub ahead of print).","DOI":"10.1007\/s10157-018-1603-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Takada T, Masaki T, Hoshiyama A, Toki T, Kamata Y, Shichiri M. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide. Nephrology (Carlton) 23: 883-886, 2018.","DOI":"10.1111\/nep.13390"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takagi K, Sato N, Ishihara S, et al. Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria. Heart Vessels 33: 413-420, 2018.","DOI":"10.1007\/s00380-017-1066-4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/11\/58_2174-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T23:56:25Z","timestamp":1559346985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/11\/58_2174-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2174-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}